

# **New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer**

Dec 08, 2021

---

**Source URL:** <https://prod1.novartis.com/us-en/news/media-releases/new-kisqali-data-shows-consistent-overall-survival-benefit-across-genomic-and-clinical-subtypes-interest-hrher2-metastatic-breast-cancer-0>

## **List of links present in page**

1. <https://prod1.novartis.com/us-en/us-en/news/media-releases/new-kisqali-data-shows-consistent-overall-survival-benefit-across-genomic-and-clinical-subtypes-interest-hrher2-metastatic-breast-cancer-0>